Antibody-Drug Conjugates (ADCs) combine highly potent chemotherapy agents (payloads) with target-specific monoclonal antibodies through a covalent linker molecule. These biomolecules result in a target-tracking pharmaceutical showing strong efficacy in cancer therapies.
Discover the 3 facts you need to know about Antibody Drug Conjugates.
The vast majority of ADCs are comprised of a monoclonal antibody conjugated to a cytotoxic payload.
However, there are also many different forms of conjugated therapies including non-cytotoxic compounds as well.
Antibody-Drug Conjugates are constructed from three primary parts: mAb, linker, and payload. The most common mAb used is either fully or partially humanized IgG1. The linker used is either cleavable or non-cleavable, and the linkage is carried out through a variety of different conjugation technologies. The most common of those are stochastic cysteine, stochastic lysine, and engineered cysteine (site-specific). Common payloads include auristatins, maytansins, PBDs and irinotecans, with a trend towards increased diversity.
Combining these elements creates the broad diversity of ADC molecules currently in pre-clinical and clinical development.